START Doses 1st US Patient in Moderna’s Pan-Tumor Antigen Therapy Study in Solid Tumors
START Doses First U.S. Patient in Moderna’s Phase 1 Clinical Trial of mRNA-4106, a Pan-Tumor Antigen Therapy Candidate, in Solid Tumors
Major study milestone highlights START’s commitment to bringing novel cancer therapies to patients through community-based early-phase clinical trials
The START Center for Cancer Research (“START”), the world’s largest early-phase community-based oncology site network, today announced the dosing of the first U.S. participant in Moderna’s Phase 1 study evaluating mRNA-4106, a novel Pan-Tumor Antigen Therapy candidate, in patients with advanced or metastatic solid tumors.
The first dose was administered at START San Antonio by Dr. Amita Patnaik, who shared,
“mRNA represents a bold new frontier in cancer immunotherapy, and we’re proud to provide our patients access to this innovative treatment as part of a first-in-human trial. At START, our mission is to ensure that scientific breakthroughs translate into real-world options for patients – this study is a powerful example of that commitment.”
The Phase 1 trial (ClinicalTrials.gov identifier: NCT06880549) will evaluate the safety, pharmacodynamics, immunogenicity and preliminary efficacy of mRNA-4106 administered alone and in combination with checkpoint inhibitor therapy. mRNA-4106’s multivalent approach aims to broaden treatment options for patients with cancer, advancing the field beyond single-targeted immunotherapies.
“This milestone reflects the core of who we are at START – accelerating the next generation of cancer therapies by bringing them directly to patients in the communities where they live. We’re proud to support Moderna in advancing this innovation into the clinic, reinforcing our commitment to faster, more accessible early phase trials that expand opportunity and impact for patients and sponsors alike,” said Nick Slack, MBE, Chairman and CEO of START.
“With mRNA-4106, we sought to design an inclusive therapy that encodes for antigens commonly shared across patients and tumor types. We are thrilled to be able to bring this medicine to trial participants, and in partnership with forward-thinking site networks like START, further showcase the promise of mRNA to transform cancer care,” said Dr. Rose Loughlin, Executive Vice President of Research at Moderna.
START’s participation in this trial reinforces its leadership in accelerating access to transformative therapies, delivering on its mission of “Hope Through Access” for patients worldwide.
You can read more posts featuring The START Center for Cancer Research and Moderna.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023